Join

Compare · NVO vs PNT

NVO vs PNT

Side-by-side comparison of Novo Nordisk A/S (NVO) and POINT Biopharma Global Inc. (PNT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both NVO and PNT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $191.82B, about 337.8x PNT ($567.8M).
  • NVO has hit the wire 8 times in the past 4 weeks while PNT has been quiet.
  • NVO has more recent analyst coverage (25 ratings vs 13 for PNT).
MetricNVOPNT
Company
Novo Nordisk A/S
POINT Biopharma Global Inc.
Price
$41.01-4.51%
$12.51+0.24%
Market cap
$191.82B
$567.8M
1M return
-10.44%
-
1Y return
-45.66%
-
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2020
News (4w)
8
0
Recent ratings
25
13
NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

PNT

POINT Biopharma Global Inc.

POINT Biopharma Global Inc., a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer; and PNT-2004, a fibroblast activation protein-a targeted radioligand to treat solid tumors. POINT Biopharma Global Inc. is based in Indianapolis, Indiana.

Latest NVO

Latest PNT